{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T22:03:28Z","timestamp":1783980208940,"version":"3.55.0"},"reference-count":84,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Methadone, a medication for opioid use disorder, is underused in the US response to the opioid overdose crisis. Under federal law, methadone can be offered in pharmacies via medication units, although a change to federal statutes or regulations could allow more options for pharmacists to dispense methadone.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To analyze innovative return on investment (ROI) for 2 pharmacy-based models: (1) pharmacy-based medication unit and (2) pharmacist-dispensed methadone.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cross-sectional economic evaluation, conducted from March 13, 2024, to August 22, 2025, created 2 models for pharmacy-based methadone dispensed at community-based pharmacies in the US to people who are stable on methadone maintenance treatment and who were referred by the opioid treatment program (OTP) or who recently initiated treatment due to the new option for pharmacy dispensing: (1) an OTP and a pharmacy partner to operate a medication unit in the pharmacy wherein OTP clinicians prescribe and pharmacists dispense methadone and (2) regulatory changes that allow medical professionals to prescribe methadone and pharmacists to dispense the medication. Each model included startup costs plus 3 years of operational costs and revenue. Input data were extracted from key informant interviews, a time-motion study, and the literature. Data were analyzed from June 2024 to July 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Models addressed clinical services, anticipated consumers, potential competitors, key differentiators, and critical success factors. Input data were combined with microcosting methodology and enumerated minimum, best, and maximum values (PertBeta distributions) for 121 key inputs. A total of 10\u202f000 Monte Carlo simulations were conducted to obtain 95% uncertainty intervals (UIs). Values are presented in 2024 US dollars.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary study outcomes were ROI ratios and net profits after 3 years in operation.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The medication unit model (model 1) assumed a total of 3429 (95% UI, 1385-6244) client visits over the 3 years, indicating a mean (SD) of 95 (36) visits per month. For the pharmacist-dispensed model (model 2), the total number of client visits was estimated as 793 (95% UI, 531-1167), indicating a mean (SD) of 22 (5) visits per month. For model 1, over 3 years, a pharmacy would net $3.53 (95% UI, $1.14-$6.99) for every $1.00 spent, yielding a profit of $96\u202f904 (95% UI, $5365-$267\u202f451), including a 93.8% likelihood of netting $15\u202f000 by year 3. For model 2, over 3 years, a pharmacy would net $2.64 (95% UI, $2.04-$3.41) for every $1.00, yielding a profit of $23\u202f844 (95% UI, $15\u202f045-$36\u202f546), including a 97.6% likelihood of netting $15\u202f000 or more by year 3.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this economic evaluation of 2 pharmacy-based methadone business models, both models demonstrated positive ROI over 3 years. This finding suggests that increased access to methadone\u2014a key step in reducing overdose deaths\u2014can be profitable for community pharmacies. Changes to federal statutes or regulations may be needed, depending on the preferred model.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.0703","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T15:30:39Z","timestamp":1773675039000},"page":"e260703","source":"Crossref","is-referenced-by-count":2,"title":["Treating Opioid Use Disorder With Methadone in Pharmacies"],"prefix":"10.1001","volume":"9","author":[{"given":"Cynthia A.","family":"Tschampl","sequence":"first","affiliation":[{"name":"The Heller School for Social Policy and Management, Brandeis University, Waltham, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sage R.","family":"Feltus","sequence":"additional","affiliation":[{"name":"Department of Health Law, Policy & Management, Boston University School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Soranno","sequence":"additional","affiliation":[{"name":"The Heller School for Social Policy and Management, Brandeis University, Waltham, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Bratberg","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, University of Rhode Island College of Pharmacy, Kingston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen T.","family":"Stewart","sequence":"additional","affiliation":[{"name":"Department of Health Law, Policy & Management, Boston University School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray","family":"Dawson","sequence":"additional","affiliation":[{"name":"The Heller School for Social Policy and Management, Brandeis University, Waltham, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Traci C.","family":"Green","sequence":"additional","affiliation":[{"name":"The Heller School for Social Policy and Management, Brandeis University, Waltham, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"issue":"9","key":"zoi260046r3","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","article-title":"Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis.","volume":"78","author":"Santo","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"zoi260046r5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/ADM.0000000000001246","article-title":"Dispensing methadone at hospital discharge: one hospital\u2019s approach to implementing the \u201c72-hour rule\u201d change.","volume":"18","author":"Skogrand","year":"2024","journal-title":"J Addict Med"},{"issue":"1","key":"zoi260046r8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13722-022-00316-3","article-title":"Cumulative barriers to retention in methadone treatment among adults from rural and small urban communities.","volume":"17","author":"Pasman","year":"2022","journal-title":"Addict Sci Clin Pract"},{"issue":"4","key":"zoi260046r9","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.7028","article-title":"Assessment of community-level vulnerability and access to medications for opioid use disorder.","volume":"5","author":"Joudrey","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"3","key":"zoi260046r10","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1080\/00952990.2019.1694536","article-title":"A systematic review of rural-specific barriers to medication treatment for opioid use disorder in the United States.","volume":"46","author":"Lister","year":"2020","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"4","key":"zoi260046r11","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1001\/jamapsychiatry.2013.4450","article-title":"Access to treatment for opioid dependence in rural America: challenges and future directions.","volume":"71","author":"Sigmon","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"zoi260046r12","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2024.116660","article-title":"Barriers to opioid use disorder treatment among people who use drugs in the rural United States: a qualitative, multi-site study.","volume":"346","author":"Stopka","year":"2024","journal-title":"Soc Sci Med"},{"issue":"8-9","key":"zoi260046r13","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1177\/10497323221104315","article-title":"Treatment experiences among people who use opioids: a social ecological approach.","volume":"32","author":"Kahn","year":"2022","journal-title":"Qual Health Res"},{"issue":"3","key":"zoi260046r14","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1097\/ADM.0000000000000308","article-title":"Treating women who are pregnant and parenting for opioid use disorder and the concurrent care of their infants and children: literature review to support national guidance.","volume":"11","author":"Klaman","year":"2017","journal-title":"J Addict Med"},{"issue":"3","key":"zoi260046r15","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/02791072.2009.10400539","article-title":"Premature discharge from methadone treatment: patient perspectives.","volume":"41","author":"Reisinger","year":"2009","journal-title":"J Psychoactive Drugs"},{"issue":"S2","key":"zoi260046r16","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.2105\/AJPH.2021.306665","article-title":"The Methadone Manifesto: treatment experiences and policy recommendations from methadone patient activists.","volume":"112","author":"Simon","year":"2022","journal-title":"Am J Public Health"},{"issue":"1","key":"zoi260046r20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13722-023-00399-6","article-title":"Patient perspectives on community pharmacy administered and dispensing of methadone treatment for opioid use disorder: a qualitative study in the U.S.","volume":"18","author":"Wu","year":"2023","journal-title":"Addict Sci Clin Pract"},{"issue":"4","key":"zoi260046r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2024.102117","article-title":"Actions of the 2024 American Pharmacists Association House of Delegates, Orlando, FL, March 22\u201325, 2024.","volume":"64","year":"2024","journal-title":"J Am Pharm Assoc"},{"issue":"9","key":"zoi260046r22","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1377\/hlthaff.2025.00344","article-title":"Key-informant perspectives on pharmacy-based methadone treatment for opioid use disorder in the US.","volume":"44","author":"Stewart","year":"2025","journal-title":"Health Aff (Millwood)"},{"key":"zoi260046r23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jsat.2018.07.006","article-title":"Increased distance was associated with lower daily attendance to an opioid treatment program in Spokane County Washington.","volume":"93","author":"Amiri","year":"2018","journal-title":"J Subst Abuse Treat"},{"key":"zoi260046r24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jsat.2017.04.007","article-title":"Baseline risk factors for drug use among African-American patients during first-month induction\/stabilization on methadone.","volume":"78","author":"Lister","year":"2017","journal-title":"J Subst Abuse Treat"},{"issue":"4","key":"zoi260046r25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123687","article-title":"Factors associated with methadone treatment duration: a Cox regression analysis.","volume":"10","author":"Lin","year":"2015","journal-title":"PLoS One"},{"issue":"13","key":"zoi260046r26","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1001\/jama.2019.12562","article-title":"Drive times to opioid treatment programs in urban and rural counties in 5 US states.","volume":"322","author":"Joudrey","year":"2019","journal-title":"JAMA"},{"issue":"2","key":"zoi260046r27","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.japh.2024.01.004","article-title":"Access to community pharmacies based on drive time and by rurality across the contiguous United States.","volume":"64","author":"Sharareh","year":"2024","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"3","key":"zoi260046r28","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.japh.2023.01.013","article-title":"\u201cLike it was just everyday business\u201d: a qualitative study of pharmacy-based naloxone and syringe customer experience.","volume":"63","author":"Gray","year":"2023","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"2","key":"zoi260046r29","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1056\/NEJMc2208055","article-title":"Physician-delegated unobserved induction with buprenorphine in pharmacies.","volume":"388","author":"Green","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi260046r30","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.sapharm.2024.02.001","article-title":"\u201cI go out of my way to give them an extra smile now:\u201d a study of pharmacists who participated in Respond to Prevent, a community pharmacy intervention to accelerate provision of harm reduction materials.","volume":"20","author":"Irwin","year":"2024","journal-title":"Res Social Adm Pharm"},{"issue":"6","key":"zoi260046r31","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1016\/j.japh.2022.07.003","article-title":"Access to community pharmacies: a nationwide geographic information systems cross-sectional analysis.","volume":"62","author":"Berenbrok","year":"2022","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"1","key":"zoi260046r32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/adaw.32583","article-title":"Report: it\u2019s time for insurers to ramp up methadone coverage in 2020.","volume":"32","author":"Enos","year":"2020","journal-title":"Alcohol Drug Abuse Week"},{"key":"zoi260046r35","doi-asserted-by":"publisher","author":"Husereau","journal-title":"Health Policy OPEN","DOI":"10.1016\/j.hpopen.2021.100063"},{"issue":"10","key":"zoi260046r38","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.29869","article-title":"The purpose of time-motion studies (TMSs) in healthcare: a literature review.","volume":"14","author":"Kalne","year":"2022","journal-title":"Cureus"},{"issue":"7","key":"zoi260046r39","doi-asserted-by":"publisher","first-page":"S76","DOI":"10.1097\/MLR.0b013e31819bc064","article-title":"Microcosting quantity data collection methods.","volume":"47","author":"Frick","year":"2009","journal-title":"Med Care"},{"key":"zoi260046r68","doi-asserted-by":"publisher","author":"Wu","journal-title":"Addiction","DOI":"10.1111\/add.15641"},{"issue":"3","key":"zoi260046r69","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/00952990.2024.2364338","article-title":"A simple heuristic for allocating opioid settlement funding to reduce overdose mortality in the United States.","volume":"50","author":"Skinner","year":"2024","journal-title":"Am J Drug Alcohol Abuse"},{"key":"zoi260046r72","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104487","article-title":"Comparing methadone policy and practice in France and the US: implications for US policy reform.","volume":"129","author":"Englander","year":"2024","journal-title":"Int J Drug Policy"},{"key":"zoi260046r74","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.drugpo.2019.01.020","article-title":"Comparing Canadian and United States opioid agonist therapy policies.","volume":"74","author":"Priest","year":"2019","journal-title":"Int J Drug Policy"},{"issue":"1","key":"zoi260046r75","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12954-025-01238-4","article-title":"U.S. substance use harm reduction efforts: a review of the current state of policy, policy barriers, and recommendations.","volume":"22","author":"Pridgen","year":"2025","journal-title":"Harm Reduct J"},{"issue":"12","key":"zoi260046r76","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1377\/hlthaff.2024.00192","article-title":"More US pharmacies closed than opened in 2018-21; independent pharmacies, those in Black, Latinx communities most at risk.","volume":"43","author":"Guadamuz","year":"2024","journal-title":"Health Aff (Millwood)"},{"issue":"1","key":"zoi260046r77","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1001\/jamainternmed.2019.4588","article-title":"Assessment of pharmacy closures in the United States from 2009 through 2015.","volume":"180","author":"Guadamuz","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"6","key":"zoi260046r78","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1016\/j.japh.2021.07.009","article-title":"Access to pharmacies and pharmacy services in New York City, Los Angeles, Chicago, and Houston, 2015-2020.","volume":"61","author":"Guadamuz","year":"2021","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"1","key":"zoi260046r79","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.japh.2018.11.007","article-title":"Pharmacist-provided services: barriers to demonstrating value.","volume":"59","author":"Nguyen","year":"2019","journal-title":"J Am Pharm Assoc (2003)"},{"key":"zoi260046r82","doi-asserted-by":"publisher","DOI":"10.1002\/jac5.2008","author":"Hughes","year":"2024","journal-title":"JACCP"},{"issue":"5","key":"zoi260046r83","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.sapharm.2025.01.012","article-title":"Return on investment of pharmacists\u2019 services among non-hospitalized patients: a scoping review.","volume":"21","author":"Almodovar","year":"2025","journal-title":"Res Social Adm Pharm"},{"key":"zoi260046r84","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104645","article-title":"\u201cTethered to this ball and chain\u201d: women\u2019s perspectives on bodily agency within opioid treatment programs.","volume":"134","author":"McCracken","year":"2024","journal-title":"Int J Drug Policy"},{"key":"zoi260046r66","doi-asserted-by":"crossref","DOI":"10.4135\/9781412985116","volume-title":"Monte Carlo Simulation","author":"Mooney","year":"1997"},{"key":"zoi260046r1","unstructured":"Institute of Medicine (US) Committee on Federal Regulation of Methadone Treatment. In: Rettig? RA, Yarmolinsky? A, eds. Federal Regulation of Methadone Treatment. National Academies Press; 1995. Accessed April 29, 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK232108\/"},{"key":"zoi260046r2","unstructured":"National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on Medication-Assisted Treatment for Opioid Use Disorder. In: Leshner? AI, Mancher? M, eds. Medications for Opioid Use Disorder Saves Lives. National Academies Press; 2019. Accessed January 15, 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK538936\/"},{"key":"zoi260046r4","unstructured":"Woodruff? J, Bratberg? J, Feltus? SR, . Pharmacy-based methadone: analysis of current laws and regulations. Brandeis University Opioid Policy Research Center. 2024. Accessed April 23, 2025. https:\/\/legislativeanalysis.org\/wp-content\/uploads\/2024\/11\/Pharmacy-based-Methadone.pdf"},{"key":"zoi260046r6","unstructured":"Overview of opioid treatment program regulations by state. The Pew Charitable Trusts. September 19, 2022. Accessed June 25, 2025. https:\/\/pew.org\/3Qw8g8c"},{"key":"zoi260046r7","unstructured":"National Substance Use and Mental Health Services Survey (N-SUMHSS), 2023: annual detailed tables. Substance Abuse and Mental Health Services Administration. Published online 2023. Accessed January 15, 2024. https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt53013\/NSUMHSS-Annual-Detailed-Tables-23.pdf"},{"key":"zoi260046r17","unstructured":"Liberating methadone: a roadmap for change: conference proceedings and recommendations. National Coalition to Liberate Methadone, National Survivors Union, NYU Langone Center for Opioid Epidemiology and Policy. June 2024. Accessed February 3, 2025. https:\/\/drive.google.com\/file\/d\/1eRwpgfpfuR9Miphk5b7BsHRs4TEeYOBC\/view?usp=sharing"},{"key":"zoi260046r18","unstructured":"Addiction clinicians\u2019 letter to Congress. American Society of Addiction Medicine. March 30, 2023. Accessed December 1, 2025. https:\/\/downloads.asam.org\/sitefinity-production-blobs\/docs\/default-source\/advocacy\/letters-and-comments\/methadone-resources\/30.03.23_clinician-letter.pdf?sfvrsn=2efcb320_1"},{"key":"zoi260046r19","unstructured":"Stakeholders\u2019 letter to Congress. American Society of Addiction Medicine. May 16, 2023. Accessed December 1, 2025. https:\/\/downloads.asam.org\/sitefinity-production-blobs\/docs\/default-source\/advocacy\/letters-and-comments\/motaa\/08.13.24_motaa-stakeholder-endorsement.pdf?sfvrsn=f66eb4b6_1"},{"key":"zoi260046r33","unstructured":"Advocacy toolkit: eliminate the prohibition on the prescribing of methadone for OUD. American Society of Addiction Medicine. May 14, 2025. Accessed May 21, 2025. https:\/\/www.asam.org\/news\/detail\/2025\/05\/14\/advocacy-toolkit--eliminate-the-prohibition-on-the-prescribing-of-methadone-for-oud"},{"key":"zoi260046r34","unstructured":"NCPA submits comments on deregulation to OMB. National Community Pharmacists Association. Published online May 15, 2025. Accessed May 21, 2025. https:\/\/ncpa.org\/newsroom\/qam\/2025\/05\/15\/ncpa-submits-comments-deregulation-omb"},{"key":"zoi260046r36","unstructured":"Shaking the tree of science: COBRE\u2019s principles for community empowering research. Community Engaged Research Core of the COBRE on Opioids and Overdose at Rhode Island Hospital. 2022. Accessed June 15, 2025. https:\/\/heller.brandeis.edu\/opioid-policy\/pdfs\/shaking-the-tree-of-science_cobres-principals-for-community-empowering-research_april-22-2022.pdf"},{"key":"zoi260046r37","unstructured":"Occupational employment and wage statistics. U.S. Bureau of Labor Statistics. 2023. Accessed June 5, 2025. https:\/\/www.bls.gov\/oes\/2023\/may\/oes_stru.htm"},{"key":"zoi260046r40","unstructured":"File cabinet metal locking drawers plain vertical file cabinet\u20141.1mm 5 white. Litfad. Accessed June 5, 2025. https:\/\/www.litfad.com\/file-cabinet-metal-locking-drawers-plain-vertical-file-cabinet-s-2864162.html?srsltid=AfmBOortKeycfTQJzHwhqPy9m6MEl1bTHaAtsIwAm03UBXlFcXvzjfvA"},{"key":"zoi260046r41","unstructured":"Global Industrial stacking steel drawer, 17-1\/4\u201dW x 20\u201dD x 12\u201dH, black. Global Industrial. Accessed June 5, 2025. https:\/\/www.globalindustrial.com\/p\/stacking-drawer-12-h"},{"key":"zoi260046r42","unstructured":"Collaboration mobile pedestal file\u20142-drawer, white. Uline. Accessed June 5, 2025. https:\/\/www.uline.com\/Product\/Detail\/H-8260W\/Office-Storage\/Collaboration-Mobile-Pedestal-File-2-Drawer-White"},{"key":"zoi260046r43","unstructured":"Graham-Field. Grafco locking medicine cabinet\u2014safe narcotic, drug & medical storage\u2014steel double doors & locks. Amazon.com. Accessed June 5, 2025. https:\/\/www.amazon.com\/Grafco-Locking-Narcotic-Various-Sizes\/dp\/B000FYZC68?th=1"},{"key":"zoi260046r44","unstructured":"Digital safe\u2014floor, fire rated, 21 x 20 x 29\u201d, 4.0 cu. ft. Uline. Accessed June 5, 2025. https:\/\/www.uline.com\/Product\/Detail\/H-8939\/Safes\/Digital-Safe-Floor-Fire-Rated-21-x-20-x-29-4-0-Cu-Ft"},{"key":"zoi260046r45","unstructured":"Global Industrial medical security cabinet w\/double key locks, 8\u201dW x 2-5\/8\u201dD x 12-1\/8\u201dH, beige. Global Industrial. Accessed June 5, 2025. https:\/\/www.globalindustrial.com\/p\/global-174-medical-security-cabinet-8-w-x-2-5-8-d-x-12-1-8-h-2-key-locks-sand"},{"key":"zoi260046r46","unstructured":"Global Industrial small narcotics cabinet, double door\/double lock, 12\u201dW x 8\u201dD x 15\u201dH, beige. Global Industrial. Accessed June 5, 2025. https:\/\/www.globalindustrial.com\/p\/global-industrial-153-small-narcotics-cabinet-double-door-double-lock-12-w-x-8-d-x-15-h-beige"},{"key":"zoi260046r47","unstructured":"Calibrex adjustable bottle top dispenser, pharmacy grade, 1.0 to 10ml. LabDirect. Accessed June 6, 2025. https:\/\/www.labdirect.com.au\/calibrex-adjustable-bottle-top-dispenser-pharmacy-grade-1-0-to-10ml\/"},{"key":"zoi260046r48","unstructured":"BR4600330 BRAND Dispensette S digital bottle-top dispenser volume range 0.5-5 mL, without recirculation valve. Sigma-Aldrich. Accessed June 6, 2025. https:\/\/www.sigmaaldrich.com\/US\/en\/product\/aldrich\/br4600330?utm_source=google%2Cgoogle&utm_medium=organicshopping%2Ccpc&utm_campaign=21043330280&utm_content=&gclid=Cj0KCQjwxsm3BhDrARIsAMtVz6Oxm_XVuJwaGQgiNAhnsADW1I9GYBgY0RpdkOF0RND3RqP1fbHtfVcaAlWUEALw_wcB"},{"key":"zoi260046r49","unstructured":"Automated liquid methadone dispensing series\u2014LabTec. Part#:200-METH-SYSTEM. Parker Hannifin. Accessed June 6, 2025. https:\/\/ph.parker.com\/us\/en\/product\/automated-liquid-methadone-dispensing-system-labtec\/200-meth-system"},{"key":"zoi260046r50","unstructured":"Zebra ZD420t-HC TT printer. Barcode Factory. Accessed June 6, 2025. https:\/\/www.barcodefactory.com\/zebra\/printers\/zd420t-hc\/zd42h42-t01e00ez?gad_source=1&gclid=CjwKCAiA6aW6BhBqEiwA6KzDc-fFL3yBm82pXX6iupVkP2CI_6k6YhmaN2Mq49rChpdl9RSF8uCzuxoC1uUQAvD_BwE"},{"key":"zoi260046r51","unstructured":"Brother QL-600 desktop monochrome label printer, up to 2.4\u201d label width. Amazon.com. Accessed June 6, 2025. https:\/\/www.amazon.com\/dp\/B085D3BZQL?ref=cm_sw_r_cp_ud_dp_NJFEHG2QCJCNERNBKDNH&ref_=cm_sw_r_cp_ud_dp_NJFEHG2QCJCNERNBKDNH&social_share=cm_sw_r_cp_ud_dp_NJFEHG2QCJCNERNBKDNH&_encoding=UTF8&peakEvent=3&dealEvent=0&skipTwisterOG=1&th=1"},{"key":"zoi260046r52","unstructured":"Healthcare label printers. Supplyline Auto ID. November 2024. Accessed June 6, 2025. https:\/\/www.supplylineid.com\/shop\/category\/printers\/healthcare-label-printers\/"},{"key":"zoi260046r53","unstructured":"Buy iPad. November 2024. Apple Inc. Accessed June 27, 2025. https:\/\/www.apple.com\/shop\/buy-ipad\/ipad"},{"key":"zoi260046r54","unstructured":"Logitech H390 wired headphones with mic, USB-A headset with microphone for PC, noise cancelling microphone for video meetings, music, gaming\u2014black. Amazon.com. Accessed June 27, 2025. https:\/\/www.amazon.com\/dp\/B000UXZQ42?ref=cm_sw_r_cp_ud_dp_865KTYZ2Q0PGA6BGZ5Y0&ref_=cm_sw_r_cp_ud_dp_865KTYZ2Q0PGA6BGZ5Y0&social_share=cm_sw_r_cp_ud_dp_865KTYZ2Q0PGA6BGZ5Y0&skipTwisterOG=1&th=1"},{"key":"zoi260046r55","unstructured":"2023 NSDUH Annual National Report. Substance Abuse and Mental Health Services Administration. 2024. Accessed January 15, 2024. https:\/\/www.samhsa.gov\/data\/report\/2023-nsduh-annual-national-report"},{"key":"zoi260046r56","unstructured":"21 CFR part 1301\u2013registration of manufacturers, distributors, and dispensers of controlled substances. Code of Federal Regulations. Accessed November 12, 2024. https:\/\/www.ecfr.gov\/current\/title-21\/part-1301"},{"key":"zoi260046r57","unstructured":"400 Count, Care Touch alcohol wipes individually wrapped\u2014prep pads with 70% isopropyl alcohol. Amazon.com. Accessed June 5, 2025. https:\/\/www.amazon.com\/dp\/B06XS38XH6?_encoding=UTF8&ref=cm_sw_r_cp_ud_dp_V7S5KCYZ18F7FW6BXGRW&ref_=cm_sw_r_cp_ud_dp_V7S5KCYZ18F7FW6BXGRW&social_share=cm_sw_r_cp_ud_dp_V7S5KCYZ18F7FW6BXGRW&skipTwisterOG=1.&th=1"},{"key":"zoi260046r58","unstructured":"Final rule payment rates for opioid treatment programs. Centers for Medicare & Medicaid Services. Accessed June 5, 2025. https:\/\/www.cms.gov\/medicare\/payment\/opioid-treatment-programs-otp\/billing-payment\/otp-payment-rates"},{"key":"zoi260046r59","unstructured":"Average rent of retail real state in the United States in 4th quarter 2023, by property type (in U.S. dollars per square foot). Statista. 2023. Accessed June 6, 2025. https:\/\/www.statista.com\/statistics\/1379047\/retail-real-estate-rent-by-property-type-usa\/"},{"key":"zoi260046r60","unstructured":"Medicaid covered outpatient prescription drug reimbursement information by state. Medicaid.gov. Accessed June 16, 2025. https:\/\/www.medicaid.gov\/medicaid\/prescription-drugs\/state-prescription-drug-resources\/medicaid-covered-outpatient-prescription-drug-reimbursement-information-state"},{"key":"zoi260046r61","unstructured":"21 CFR Part 1301\u2014security requirements. Code of Federal Regulations. Accessed June 11, 2025. https:\/\/www.ecfr.gov\/current\/title-21\/part-1301\/subject-group-ECFRa7ff8142033a7a2"},{"key":"zoi260046r62","unstructured":"Diversion Control Division: registration. Drug Enforcement Administration. Accessed June 5, 2025. https:\/\/www.deadiversion.usdoj.gov\/drugreg\/registration.html"},{"key":"zoi260046r63","unstructured":"Increased reimbursement of medications for the treatment of opioid use disorder. Director, Department of Medical Assistance Services, Commonwealth of Virginia. 2022. Accessed June 5, 2025. https:\/\/vamedicaid.dmas.virginia.gov\/memo\/increased-reimbursement-medications-treatment-opioid-use-disorder"},{"key":"zoi260046r64","unstructured":"Medicare COVID-19 vaccine shot payment. Centers for Medicare & Medicaid Services. 2025. Accessed June 5, 2025. https:\/\/www.cms.gov\/medicare\/payment\/covid-19-vaccine-toolkit\/medicare-covid-19-vaccine-shot-payment"},{"key":"zoi260046r65","unstructured":"Incentive grants. APhA Foundation, American Pharmacists Association. Accessed June 16, 2025. https:\/\/www.aphafoundation.org\/incentive-grants"},{"key":"zoi260046r67","unstructured":"@Risk: risk analysis software in Excel. Lumivero. Accessed January 27, 2026. https:\/\/www.palisade.com\/risk\/"},{"key":"zoi260046r70","unstructured":"The principles for the use of funds from the opioid litigation. Johns Hopkins Bloomberg School of Public Health. Accessed June 16, 2025. https:\/\/opioidprinciples.jhsph.edu\/"},{"key":"zoi260046r71","unstructured":"In Australia, primary care and pharmacies deliver methadone. The Pew Charitable Trusts. May 17, 2023. Accessed February 19, 2025. https:\/\/pew.org\/3BwTVU4"},{"key":"zoi260046r73","unstructured":"How can patients access methadone in other countries? The Pew Charitable Trusts. Accessed June 16, 2025. https:\/\/pew.org\/3M8T297"},{"key":"zoi260046r80","unstructured":"Critical access hospital. Centers for Medicare & Medicaid Services. Published online March 2021. Accessed May 12, 2025. https:\/\/www.hrsa.gov\/sites\/default\/files\/hrsa\/opa\/critical-access-hospital-factsheet.pdf"},{"key":"zoi260046r81","unstructured":"Administrative Code. Title 89: Social Services; Chapter I: Department of Healthcare and Family Services; Subchapter d: Medical Programs; Part 140 Medical Payment; Section 140.439 Critical Access Care Pharmacy Payment. Illinois General Assembly. Accessed May 12, 2025. https:\/\/www.ilga.gov\/commission\/jcar\/admincode\/089\/089001400D04390R.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2846503\/tschampl_2026_oi_260046_1773073669.69078.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T15:31:00Z","timestamp":1773675060000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2846503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":84,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.0703","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]}}}